Methamphetamine in your caseload

Methamphetamine is Australia's most widely used illicit stimulant by population-level consumption, and yet it is substantially underrepresented in primary care AOD screening relative to alcohol and cannabis. The reasons are partly structural , validated brief screening tools have historically been less embedded in primary care workflows for stimulants , and partly related to the demographics of methamphetamine use, which span occupational groups less typically associated with AOD presentations.

Understanding how methamphetamine presents in non-treatment-seeking populations, how to assess it efficiently using validated instruments, and what brief intervention evidence supports for this substance class, is increasingly a core primary care competency.

The clinical profile of methamphetamine presentations

The presentations that reach primary care and community AOD services are not uniform. Clinicians who expect the severe end-stage presentations seen in acute hospital settings will miss the much more common moderate-use presentations.

Acute intoxication in primary care is relatively rare , most patients don't present while acutely intoxicated. When it does occur, the clinical picture includes elevated heart rate and blood pressure, hyperthermia, agitation, pressured speech, and reduced need for sleep. In severe cases, cardiac arrhythmia, chest pain, and psychotic symptoms may be present and require emergency referral.

Stimulant use disorder on the spectrum from harmful use to dependence is what most primary care encounters will involve. Key presentations include:

• Sleep disturbance , both insomnia during use and hypersomnia during withdrawal , presenting as chronic fatigue
• Depressive symptoms and anhedonia in the days following use, often misattributed to comorbid depression
• Anxiety, paranoia, and social withdrawal that the patient may attribute to personality or life circumstances
• Cardiovascular symptoms including palpitations and chest tightness
• Weight loss and poor nutritional status in heavier users
• Dental deterioration in longer-term users ("meth mouth" is well documented but may not be visible until advanced)

Stimulant-induced psychosis warrants specific attention. This is not exclusive to the severe end of the use spectrum , acute stimulant psychosis can occur in people who do not otherwise meet criteria for stimulant use disorder, and transient paranoid ideation is common across a broader range of use. Clinicians should enquire routinely about paranoid thoughts, perceptual disturbances, and episodes of confusion following methamphetamine use.

Validated assessment tools

The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), developed by the World Health Organisation, is the most appropriate brief screening instrument for stimulant use in primary care settings. Unlike the AUDIT, which is specific to alcohol, the ASSIST covers all major substance classes and generates a risk score for each that can guide clinical conversation.

For methamphetamine, an ASSIST score of 4–26 indicates moderate risk and is the threshold for brief intervention. Scores above 27 indicate high risk and suggest referral for more specialised assessment.

The Timeline Followback (TLFB) method , a structured retrospective calendar approach to substance use history , is particularly useful for establishing frequency and quantity data for methamphetamine use, where self-report is more variable than for alcohol. Administered over 30 or 90 days, it provides a more granular picture of use patterns than simple frequency questions.

The Severity of Dependence Scale (SDS) is a brief five-item instrument validated for stimulant use that rapidly assesses the psychological dimensions of dependence , preoccupation, impaired control, anxiety about stopping. It takes under two minutes and helps differentiate harmful use from dependence in terms of clinical need.

What brief intervention looks like for stimulants

The evidence base for brief intervention in methamphetamine use is less developed than for alcohol, but it is not absent. The MATRSS trial and subsequent work support the use of motivational interviewing and cognitive behavioural approaches adapted for stimulant use disorder. What the evidence does not support is treating stimulant use disorder as a simple willpower or information problem.

Key principles for brief intervention with methamphetamine-using patients:

Acknowledge ambivalence without resolving it prematurely. Patients in the pre-contemplation and contemplation stages of change are not ready for a change plan, and confrontational or directive approaches reliably increase resistance. Motivational interviewing techniques , reflective listening, exploring discrepancy, eliciting change talk , are better matched to where most patients presenting to primary care will be.

Address the mental health sequelae directly. The relationship between methamphetamine use and the patient's presenting mental health symptoms , anxiety, depression, paranoia, sleep disturbance , is a productive and non-confrontational entry point. Most patients will have not clearly connected their psychological symptoms to their methamphetamine use. Helping make this connection explicit, non-judgmentally, is often the most useful thing a brief consultation can do.

There is no approved pharmacotherapy for methamphetamine use disorder in Australia, which changes the brief intervention calculus relative to alcohol or opioids. Naltrexone has some emerging evidence for stimulant use disorder but is not approved for this indication. The NDARC Treatment Options for Methamphetamine guidance is the most current Australian clinical resource. Treatment is psychosocial, and warm referral to a specialist AOD service or psychologist experienced in stimulant use disorder is the appropriate pathway for moderate to high ASSIST scores.

Sleep and nutrition are often underemphasised in brief intervention for methamphetamine. Addressing the physiological recovery from use , sleep hygiene, nutrition, cardiovascular health monitoring , provides a clinically meaningful harm reduction focus that doesn't require a decision about cessation.

Self-monitoring as a between-session tool

For patients not ready for formal treatment referral, digital self-monitoring tools can bridge the gap between clinical encounter and behaviour change consideration. The evidence base for self-monitoring in pre-contemplative substance use populations is reviewed in digital self-monitoring as a between-session tool.

The specific value for methamphetamine-using patients is in making the use-to-mood correlation visible over time , the pattern that connects use occasions to the mood and functioning consequences in subsequent days. For patients who attribute their anxiety and depressive symptoms to other causes, accurate self-monitoring data that surfaces this correlation is often more persuasive than clinical assertions that their drug use is affecting their mental health.

Recommending a tool that is anonymous and doesn't require clinical oversight can improve uptake with patients who are wary of perceived surveillance , a particular concern in methamphetamine-using populations where involvement with the justice system is a realistic fear. See why anonymity improves self-reporting in substance use treatment for the evidence base.

---

ayodee is an anonymous self-monitoring tool for substance use, mood, and wellbeing. Clinicians can recommend it as a between-session tool without it creating a clinical data trail. Free at ayodee.app.